NIFTY 50▼23,995.35
-309.00 (-1.27%)
SENSEX▼78,782.24
-941.88 (-1.18%)
NIFTY BANK▼51,215.25
-458.65 (-0.89%)
TATA MOTORS▼824.10
-19.35 (-2.29%)
SUZLON ENERGY▼66.32
-1.82 (-2.67%)
TATA STEEL▼146.95
-2.80 (-1.87%)
INDIAN RAILWAY FINANCE CORP▼153.24
-4.87 (-3.08%)
TATA POWER▼429.05
-16.40 (-3.68%)
RAIL VIKAS NIGAM▼446.20
-24.75 (-5.26%)
RELIANCE INDUSTRIES▼1,302.15
-36.50 (-2.73%)
VODAFONE IDEA▼7.88
-0.57 (-6.75%)
ZOMATO▼245.08
-3.91 (-1.57%)
RELIANCE POWER▼42.03
-1.00 (-2.32%)
INDIAN RENEWABLE ENERGY▼205.38
-6.60 (-3.11%)
ADANI POWER▼585.00
-12.35 (-2.07%)
YES BANK▼20.33
-0.38 (-1.83%)
STATE BANK OF INDIA▲829.85
8.65 (1.05%)
NHPC▼83.30
-0.83 (-0.99%)
HDFC BANK▼1,714.10
-23.20 (-1.34%)
OLA ELECTRIC MOBILITY LTD▼80.84
-2.00 (-2.41%)
JIO FIN SERVICES LTD▼319.85
-6.35 (-1.95%)
INDIAN OIL CORP▼138.93
-6.06 (-4.18%)
BHARAT ELECTRONICS▼284.15
-4.50 (-1.56%)
MRF▼1,20,876.75
-2453.55 (-1.99%)
GTL INFRA▼2.11
-0.07 (-3.21%)
ADANI PORT & SEZ▼1,349.25
-45.15 (-3.24%)
JAIPRAKASH POWER VENTURES▼17.88
-0.59 (-3.19%)
ITC▼484.60
-5.70 (-1.16%)
Nippon AMC - NETF Pharma
PHARMABEES
₹23.12-₹0.24 (-1.03%) TodayLast updated on 04 Nov, 2024 | 15:55 IST
Nippon AMC - NETF Pharma Chart
Please wait...
Fund overview
About
Open ₹23.36 | Close ₹23.36 | Volume 36,80,783 | Avg. traded ₹23.02 |
Circuit range ₹18.49 - ₹27.74 | Day range ₹22.84 - ₹23.57 | Year range ₹15.11 - ₹24.53 | |
AUM ₹851.53 Cr | ManagersHimanshu Mange | Launch Date 06 Jul 2021 |
Nippon AMC - NETF Pharma
About Nippon India Nifty Pharma ETF
- The Nippon India Nifty Pharma ETF is an open-ended mutual fund offered by Nippon India Mutual Fund.
- The scheme primarily invests in pharma stocks.
- Nippon India Nifty Pharma ETF was launched on July 2, 2021.
- The ETF has assets under management (AUM) at ₹706.41 crore as of July 31.
- Himanshu Mange has been the fund manager of Nippon India Nifty Pharma ETF since December 2021.
- The ETF units are listed on both NSE and BSE.
- Retail investors can purchase units through a demat account with a registered broker.
Investment Objective & Benchmark
- The ETF is benchmarked against the Nifty Pharma Index Total Return Index, which tracks the top-performing companies in areas like sustainability and growth.
- This fund's objective is to generate returns by investing in the same stocks as the Nifty Pharma Index, closely matching its performance, though some differences may occur.
- The risk profile level of Nippon India Nifty Pharma ETF is very high.
- The Nifty Pharma Index typically includes large-cap pharmaceutical companies which are considered more stable than smaller companies.
- This ETF is suitable for investors looking to gain exposure to the pharmaceutical sector without having to pick individual stocks.
- It can be a good option for those who believe in the growth potential of the Indian pharma industry.
- The stocks in this ETF are weighted according to their proportion in the Nifty Pharma Index, based on free-float market capitalisation, which considers only the shares available for trading.
- Companies are selected based on their market-cap ratings, focusing on those with the highest rankings in the pharma sectors. The portfolio includes a mix of large-cap and mid-cap companies that are leaders in their industries and are expected to benefit from India's growth.
Asset Allocation & Portfolio Composition
- The ETF holds 99.68% of its fund in equity and 0.32% in cash.
- The scheme invests in companies across market capitalisations–15.25% in giant, 33.95% in large-cap, 41.29% in mid-cap and 9.50% in small-cap.
- The ETF's sector allocation is predominantly focused on healthcare, comprising 99.68% of the fund.
- Top 10 Holdings of stocks are around 80.73% of this ETF’s asset allocation.
The top 10 company holdings in this ETF include:
- Sun Pharmaceutical Industries Limited - 24.62%
- Dr Reddy's Laboratories Limited - 10.90%
- Cipla Limited - 10.75%
- Divi's Laboratories Limited - 8.32%
- Lupin Limited - 6.13%
- Aurobindo Pharma Limited - 5.35%
- Zydus Lifesciences Limited - 4.16%
- Torrent Pharmaceuticals Limited - 3.85%
- Alkem Laboratories Limited - 3.54%
- Glenmark Pharmaceuticals Limited - 2.91%
In the last one year, the ETF has given a return of 45.6% compared to its benchmark index’s yield of 46% as of July 31, 2024.
Since its Inception, the ETF has given an annualised return of 14.68% to its investors as of July 31, 2024.
Key indicators
Tracking index Nifty Pharma |
Expense Ratio0.21% |
Tracking error 0.04% |
Learn more
Investment checklist: (2/6)
Liquidity
Fund size
Expense Ratio
Tracking error
Returns vs FD Rates
Entry Point
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Returns
Returns vs Benchmark
Compare the returns of this fund with
NIFTY 50
This ETF
Nifty 50
Please wait...
Learn more
Nippon AMC - NETF Pharma Price history
Day | Open | Close | Change % |
---|---|---|---|
Mon, Nov 4 2024 | ₹23.36 | ₹23.12 | -1.03% |
Fri, Nov 1 2024 | ₹23.47 | ₹23.36 | |
Thu, Oct 31 2024 | ₹23.55 | ₹23.17 | |
Wed, Oct 30 2024 | ₹23.33 | ₹22.84 | -1.04% |
Tue, Oct 29 2024 | ₹23.58 | ₹23.08 | -1.07% |
Mon, Oct 28 2024 | ₹23.65 | ₹23.33 | |
Fri, Oct 25 2024 | ₹24.02 | ₹22.97 | -0.04% |
Thu, Oct 24 2024 | ₹23.55 | ₹22.98 |
Composition
What's in fund
Name | Holdings |
---|---|
SUNPHARMASun Pharmaceuticals Industries Ltd | 25.54% |
500087Cipla Ltd | 11.13% |
DRREDDYDr Reddy's Laboratories Ltd | 10.11% |
DIVISLABDivi's Laboratories Ltd | 8.48% |
500257Lupin Ltd | 6.48% |
AUROPHARMAAurobindo Pharma Ltd | 5.01% |
1/4
More